Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

奥西默替尼 培美曲塞 医学 内科学 肿瘤科 酪氨酸激酶抑制剂 肺癌 T790米 非小细胞肺癌 酪氨酸激酶 癌症研究 顺铂 化疗 表皮生长因子受体 癌症 埃罗替尼 吉非替尼 受体 A549电池
作者
Vassiliki A. Papadimitrakopoulou,Tony Mok,Ji‐Youn Han,Myung‐Ju Ahn,Angelo Delmonte,Suresh S. Ramalingam,Seung‐Whan Kim,Frances A. Shepherd,Janessa Laskin,Yong He,Hiroaki Akamatsu,Willemijn S.M.E. Theelen,Wu‐Chou Su,Thomas John,Martin Sebastian,Helen Mann,Michele Miranda,Gianluca Laus,Yuri Rukazenkov,Yi‐Long Wu
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:31 (11): 1536-1544 被引量:222
标识
DOI:10.1016/j.annonc.2020.08.2100
摘要

•Median OS with osimertinib was 26.8 months versus 22.5 months with platinum–pemetrexed (HR 0.87, 95% CI 0.67–1.12; P = 0.277).•The lack of a significant survival benefit could reflect high percentage (73%) of platinum–pemetrexed to osimertinib crossover.•Analysis of OS adjusted for crossover showed an HR of 0.54 (95% CI 0.18–1.60).•Among patients receiving subsequent anticancer therapy, platinum chemotherapy was the most common after osimertinib (65%).•Grade ≥3 (possibly treatment-related) adverse events were observed less frequently with osimertinib (9% versus 34% with platinum–pemetrexed). BackgroundIn AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis.Patients and methodsAdult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points.ResultsA total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm.ConclusionsIn patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib.Clinical trials numberClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981. In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis. Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points. A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm. In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐观的问兰完成签到 ,获得积分10
刚刚
书生完成签到,获得积分10
刚刚
朱佳宁完成签到 ,获得积分10
1秒前
Master完成签到 ,获得积分10
2秒前
怕孤独的香菇完成签到 ,获得积分10
2秒前
光亮冬寒完成签到,获得积分10
3秒前
FashionBoy应助李李采纳,获得10
4秒前
搬砖完成签到 ,获得积分10
5秒前
kingmp2完成签到 ,获得积分10
5秒前
盼盼完成签到,获得积分10
6秒前
zcm1999完成签到 ,获得积分10
7秒前
长风完成签到 ,获得积分10
7秒前
虞无声发布了新的文献求助10
8秒前
10秒前
奋斗的妙海完成签到 ,获得积分10
11秒前
HHEHK完成签到 ,获得积分10
13秒前
胡晓龙发布了新的文献求助10
13秒前
新的旅程完成签到,获得积分10
15秒前
完犊子发布了新的文献求助10
16秒前
木康薛完成签到,获得积分10
17秒前
地德兴完成签到 ,获得积分10
17秒前
18秒前
339564965完成签到,获得积分10
19秒前
安静严青完成签到 ,获得积分10
19秒前
20秒前
柏林寒冬应助完犊子采纳,获得10
21秒前
ccc完成签到,获得积分10
21秒前
TianFuAI完成签到,获得积分10
22秒前
chee完成签到,获得积分10
23秒前
研友_ZA2B68完成签到,获得积分0
23秒前
inu1255完成签到,获得积分0
23秒前
只想顺利毕业的科研狗完成签到,获得积分10
24秒前
普鲁卡因发布了新的文献求助10
25秒前
Helios完成签到,获得积分10
26秒前
xueshidaheng完成签到,获得积分0
26秒前
BK_201完成签到,获得积分10
26秒前
风信子完成签到,获得积分10
27秒前
abiorz完成签到,获得积分0
27秒前
窗外是蔚蓝色完成签到,获得积分0
28秒前
nanostu完成签到,获得积分10
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022